Aspirin′s active metabolite salicylic acid targets high mobility group box 1 to modulate inflammatory responses

Hyong Woo Choi, Miaoying Tian, Fei Song, Emilie Venereau, Alessandro Preti, Sang Wook Park, Keith Hamilton, G. V T Swapna, Murli Manohar, Magali Moreau, Alessandra Agresti, Andrea Gorzanelli, Francesco De Marchis, Huang Wang, Marc Antonyak, Robert J. Micikas, Daniel R. Gentile, Richard A. Cerione, Frank C. Schroeder, Gaetano T. MontelioneMarco E. Bianchi, Daniel F. Klessig

Research output: Contribution to journalArticle

Abstract

Salicylic acid (SA) and its derivatives have been used for millennia to reduce pain, fever and inflammation. In addition, prophylactic use of acetylsalicylic acid, commonly known as aspirin, reduces the risk of heart attack, stroke and certain cancers. Because aspirin is rapidly de-acetylated by esterases in human plasma, much of aspirin’s bioactivity can be attributed to its primary metabolite, SA. Here we demonstrate that human high mobility group box 1 (HMGB1) is a novel SA-binding protein. SA-binding sites on HMGB1 were identified in the HMG-box domains by nuclear magnetic resonance (NMR) spectroscopic studies and confirmed by mutational analysis. Extracellular HMGB1 is a damage-associated molecular pattern molecule (DAMP), with multiple redox states. SA suppresses both the chemoattractant activity of fully reduced HMGB1 and the increased expression of proinflammatory cytokine genes and cyclooxygenase 2 (COX-2) induced by disulfide HMGB1. Natural and synthetic SA derivatives with greater potency for inhibition of HMGB1 were identified, providing proof-of-concept that new molecules with high efficacy against sterile inflammation are attainable. An HMGB1 protein mutated in one of the SA-binding sites identified by NMR chemical shift perturbation studies retained chemoattractant activity, but lost binding of and inhibition by SA and its derivatives, thereby firmly establishing that SA binding to HMGB1 directly suppresses its proinflammatory activities. Identification of HMGB1 as a pharmacological target of SA/aspirin provides new insights into the mechanisms of action of one of the world’s longest and most used natural and synthetic drugs. It may also provide an explanation for the protective effects of low-dose aspirin usage.

Original languageEnglish
Pages (from-to)526-535
Number of pages10
JournalMolecular medicine (Cambridge, Mass.)
Volume21
DOIs
Publication statusPublished - Jun 18 2015

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Aspirin′s active metabolite salicylic acid targets high mobility group box 1 to modulate inflammatory responses'. Together they form a unique fingerprint.

  • Cite this

    Choi, H. W., Tian, M., Song, F., Venereau, E., Preti, A., Park, S. W., Hamilton, K., Swapna, G. V. T., Manohar, M., Moreau, M., Agresti, A., Gorzanelli, A., De Marchis, F., Wang, H., Antonyak, M., Micikas, R. J., Gentile, D. R., Cerione, R. A., Schroeder, F. C., ... Klessig, D. F. (2015). Aspirin′s active metabolite salicylic acid targets high mobility group box 1 to modulate inflammatory responses. Molecular medicine (Cambridge, Mass.), 21, 526-535. https://doi.org/10.2119/molmed.2015.00148